- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06557642
Nitrous Oxide and EMOtional Cognition (NEMO)
Investigating the Neuropsychological Effects of Nitrous Oxide
The goal of this study is to uncover the underlying neuropsychological mechanisms of nitrous oxide, which may be relevant to its reported antidepressant effects. In particular, the study is designed to determine whether nitrous oxide changes the way in which healthy volunteers aged 18-40 years remember negative autobiographical memories.
The main question the study aims to answer is:
• Does nitrous oxide interfere with the emotional aspects of negative autobiographical memories?
Other neuropsychological effects will also be assessed (e.g., emotional processing, emotional memory, response inhibition, and cognitive flexibility).
Researchers will compare ENTONOX (50% nitrous oxide: 50% oxygen) with medical air.
Participants will:
- Attend three research visits (screening, inhalation, follow-up)
- Take part in a 30 minute inhalation session of ENTONOX or medical air
- Complete a series of cognitive tasks
- Finish a series of self-report questionnaires
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Oxford, United Kingdom, OX3 7JX
- Recruiting
- Psychiatry Department
-
Contact:
- Catherine Harmer
- Phone Number: 01865 618200
- Email: catherine.harmer@psych.ox.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 18-40 years
- Good vision and hearing
- Willing and able to give informed consent
- Body mass index (BMI) within the range of 18-35kg/m2 (This is to ensure we exclude underweight individuals who might have more substantial reactions to the nitrous oxide).
- Sufficiently fluent in English to understand tasks
- Willing to avoid drinking any alcohol from 3 days prior to Visit One until the end of Visit Three
- Willing to avoid using recreational drugs for 3 months prior to Visit One and throughout the duration of the study
Exclusion Criteria:
- Receiving or seeking treatment for any mental health condition (covered in Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders-5 (SCID) assessment in screening procedures)
- History of any mental health condition (covered in SCID assessment in screening procedures)
- Attention deficit hyperactivity disorder (ADHD) requiring treatment with stimulant or other centrally-acting drugs
- A positive drug test for any of the following: amphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine, marijuana, methadone, methamphetamine, methylenedioxymethamphetamine (MDMA), morphine, methaqualone, opiates, phencyclidine, propoxyphene, tricyclic antidepressants, tramadol, ketamine, oxycodone, cotinine, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), fentanyl, synthetic marijuana, 6-mono-acetyl-morphine (6-MAM).
- Regularly drink 14 or more units of alcohol a week
- Any eye, throat or ear surgery or a medical procedure requiring intravenous injection or line into a vein in the last 6 months
- A head injury causing concussion or unconsciousness in the past 6 months
- A collapsed lung or lung surgery (e.g., pneumothorax)
- A history of cardiac arrhythmias
- Current injuries of the face or mouth (including ulcers or dental problems)
- Dental surgery in the past month
- Deep diving or scuba diving (which has a risk of decompression sickness) in past month
- Pregnancy / intention to become pregnant during the study
- Breastfeeding during the study
- Asthma, emphysema or any medical condition that affects the lungs or breathing
- Diagnosed vitamin B12 deficiency
- Any use of recreational drugs in the last three months
- Participation in any other drug study in the last three months
- Participation in any other study with the same tasks in the last year
OPTIONAL SLEEP STUDY ADD-ON Exclusion Criteria:
- Unable to undergo cardiac monitoring
- Unable to wear the sleep patch device for full monitoring period
- Implanted neurostimulator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: ENTONOX (50% nitrous oxide:50% oxygen)
ENTONOX to be administered for 30 minutes.
|
30 minute inhalation using demand valve and mouthpiece
|
|
Placebo Comparator: Medical Air
Medical Air to be administered for 30 minutes.
|
30 minute inhalation using demand valve and mouthpiece
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Emotional Ratings of Personal Memories (Memory Reconsolidation)
Time Frame: 2 days before and 1 day after treatment
|
Negative/positive valence ratings associated with personal memories.
A series of positive and negative adjectives will be presented to participants and they will have to rate on a scale of 1(not at all) to 10 (extremely) to what extent these words apply to how they feel when recalling the memory.
|
2 days before and 1 day after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Performance on Emotional Processing Tasks
Time Frame: Immediately before and after treatment and 1 day after treatment
|
Performance on the Emotional Testing Battery (ETB), which contains an emotional word categorisation task, an emotional facial recognition task, and two emotional memory tasks.
|
Immediately before and after treatment and 1 day after treatment
|
|
Performance on Cognitive Flexibility Task
Time Frame: 1 day after treatment
|
Performance on a probabilistic reversal learning task in which participants have to learn which strategy on a computer-task leads to a reward.
|
1 day after treatment
|
|
Performance on Response Inhibition Task
Time Frame: 1 day after treatment
|
Performance on an emotional go/no-go task in which participants have to inhibit their responses to certain stimuli based on rules given at the start of each block of the task.
|
1 day after treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NEMO_Study
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMild DepressionUnited States
-
University of MinnesotaCompletedDepression SymptomsUnited States
Clinical Trials on Entonox
-
Rajavithi HospitalCompletedNulliparous | ENTONOX | Duration of LaborThailand
-
Sheffield Teaching Hospitals NHS Foundation TrustCompletedAnalgesia | Colonoscopy | Bowel Cancer Screening | EntonoxUnited Kingdom
-
University Hospital, ToulouseCompletedAcute Coronary SyndromeFrance, Réunion
-
The Cleveland ClinicCompletedLow Back Pain | Radiating PainUnited States
-
Ya'aqov AbramsUniversity of PittsburghTerminated
-
KK Women's and Children's HospitalActive, not recruitingDepression, Postpartum | Anesthesia, Obstetrical | Analgesia, ObstetricalSingapore
-
The Royal Bournemouth HospitalUnknownPatients Requiring Diagnostic Gastroscopy With SedationUnited Kingdom